Argenx Se (ARGX) Cost of Revenue (2022 - 2026)
Argenx Se (ARGX) posted Cost of Revenue of $121.0 million for Q1 2026, down 19.16% on a QoQ basis from $149.7 million in Q4 2025, and up 49.38% year-over-year from $81.0 million in Q1 2025.
Argenx Se (ARGX) Cost of Revenue (2022 - 2026) Analysis & Trends
Argenx Se's Cost of Revenue history runs 5 years deep, the most recent figure standing at $121.0 million for Q1 2026.
- Quarterly Cost of Revenue rose 49.38% year-over-year to $121.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $490.9 million (up 85.15% YoY) and the FY2025 annual result came in at $450.7 million, up 98.28% from the prior year.
- Cost of Revenue was $121.0 million for Q1 2026 at Argenx Se, down from $149.7 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $149.7 million in Q4 2025 and bottomed at $1.4 million in Q1 2022.
- A 5-year average of $55.7 million and a median of $43.2 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue jumped 1236.37% — and 2026, when it soared 49.38%.
- Argenx Se's Cost of Revenue stood at $12.8 million in 2022, then jumped by 208.75% to $39.5 million in 2023, then soared by 84.05% to $72.7 million in 2024, then surged by 106.02% to $149.7 million in 2025, then decreased by 19.16% to $121.0 million in 2026.
- Business Quant data shows ARGX's Cost of Revenue at $121.0 million in Q1 2026, $149.7 million in Q4 2025, and $109.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 121.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 207.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121.00 Mn |
| Mar 31, 2026 | 121.00 Mn |
| Dec 31, 2025 | 149.69 Mn |
| Dec 31, 2025 | 149.69 Mn |
| Sep 30, 2025 | 109.43 Mn |
| Sep 30, 2025 | 109.43 Mn |
| Jun 30, 2025 | 110.75 Mn |
| Jun 30, 2025 | 110.75 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Dec 31, 2024 | 72.66 Mn |
| Dec 31, 2024 | 72.66 Mn |
| Sep 30, 2024 | 59.07 Mn |
| Sep 30, 2024 | 59.07 Mn |
| Jun 30, 2024 | 52.38 Mn |
| Jun 30, 2024 | 52.38 Mn |
| Mar 31, 2024 | 43.18 Mn |
| Mar 31, 2024 | 43.18 Mn |
| Dec 31, 2023 | 39.48 Mn |
| Dec 31, 2023 | 39.48 Mn |